PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 我们假设沙丁胺醇预处理对轻度哮喘儿童的EIB突破具有上级保护作用，而孟鲁司特作为维持治疗加到目前的哮喘治疗方案中。本研究的次要目的是测量孟鲁司特对EBC中测量的白三烯B4（LTB 4）浓度和通过FeNO水平测量的炎症的影响。 我们假设，由于孟鲁司特是EBC中测量的半胱氨酰，并且通过FeNO水平测量炎症。 我们推测，由于莫鲁司特是一种半胱氨酰白三烯受体拮抗剂，LTB 4浓度升高的患者可能对这种药物有更大的反应。 最后，FeNo升高的患者（气道炎症的一种指标）对阿布特罗的反应与孟鲁司特不同。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is our hypothesis that pretreatment with albuterol will provide superior protection against breakthrough EIB in children with mild asthma compared to montelukast as maintenance therapy added to the current athma regimen. Secondary aims of this study are to measure the effect of montelukast on leukotriene B4 (LTB4) concentrations as measured in EBC, and on inflammation measured by FeNO level. We hypothesize that since montelukast is a cysteinyl measured in EBC, and on inflammation measured by FeNO level. We hypothesize that since motelukast is a cysteinyl leukotriene receptor antagonist, patients with elevated concentration of LTB4 may have a greater response to this mediction. Lastly, patients with elevated FeNo, a measure of airway inflammation respond differently to alubterol than montelukast.